Pyrazolo[1,5-a]pyrimidine derivatives
The Pyrazolo[1,5-a]pyrimidine derivatives represented by formula I and their pharmaceutically acceptable salts exhibit excellent MAPKAP-K2 inhibiting activity. Drugs comprising the compounds as effective ingredients are therefore expected to be useful as therapeutic or prophylactic agents for MAPKAP...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | Kosugi, Tomomi Imai, Minoru Makino, Hiroaki Takakuwa, Mika Unoki, Gen Kataoka, Kenichiro Mitchell, Dale Robert Simpson, Donald James Harris, Clifford John Le, Joelle Yamakoshi, Yuko |
| description | The Pyrazolo[1,5-a]pyrimidine derivatives represented by formula I and their pharmaceutically acceptable salts exhibit excellent MAPKAP-K2 inhibiting activity. Drugs comprising the compounds as effective ingredients are therefore expected to be useful as therapeutic or prophylactic agents for MAPKAP-K2 mediated disorder, such as inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth. |
| format | Patent |
| fullrecord | <record><control><sourceid>uspatents_EFH</sourceid><recordid>TN_cdi_uspatents_grants_07667036</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>07667036</sourcerecordid><originalsourceid>FETCH-uspatents_grants_076670363</originalsourceid><addsrcrecordid>eNrjZFANqCxKrMrPyY821DHVTYwtqCzKzM1MycxLVUhJLcosSyzJLEst5mFgTUvMKU7lhdLcDApuriHOHrqlxQWJJal5JcXx6UWJIMrA3MzM3MDYzJgIJQAmBSg4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Pyrazolo[1,5-a]pyrimidine derivatives</title><source>USPTO Issued Patents</source><creator>Kosugi, Tomomi ; Imai, Minoru ; Makino, Hiroaki ; Takakuwa, Mika ; Unoki, Gen ; Kataoka, Kenichiro ; Mitchell, Dale Robert ; Simpson, Donald James ; Harris, Clifford John ; Le, Joelle ; Yamakoshi, Yuko</creator><creatorcontrib>Kosugi, Tomomi ; Imai, Minoru ; Makino, Hiroaki ; Takakuwa, Mika ; Unoki, Gen ; Kataoka, Kenichiro ; Mitchell, Dale Robert ; Simpson, Donald James ; Harris, Clifford John ; Le, Joelle ; Yamakoshi, Yuko ; Teijin Pharma Limited</creatorcontrib><description>The Pyrazolo[1,5-a]pyrimidine derivatives represented by formula I and their pharmaceutically acceptable salts exhibit excellent MAPKAP-K2 inhibiting activity. Drugs comprising the compounds as effective ingredients are therefore expected to be useful as therapeutic or prophylactic agents for MAPKAP-K2 mediated disorder, such as inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth.</description><language>eng</language><creationdate>2010</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7667036$$EPDF$$P50$$Guspatents$$Hfree_for_read</linktopdf><link.rule.ids>230,308,776,798,881,64015</link.rule.ids><linktorsrc>$$Uhttps://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7667036$$EView_record_in_USPTO$$FView_record_in_$$GUSPTO$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Kosugi, Tomomi</creatorcontrib><creatorcontrib>Imai, Minoru</creatorcontrib><creatorcontrib>Makino, Hiroaki</creatorcontrib><creatorcontrib>Takakuwa, Mika</creatorcontrib><creatorcontrib>Unoki, Gen</creatorcontrib><creatorcontrib>Kataoka, Kenichiro</creatorcontrib><creatorcontrib>Mitchell, Dale Robert</creatorcontrib><creatorcontrib>Simpson, Donald James</creatorcontrib><creatorcontrib>Harris, Clifford John</creatorcontrib><creatorcontrib>Le, Joelle</creatorcontrib><creatorcontrib>Yamakoshi, Yuko</creatorcontrib><creatorcontrib>Teijin Pharma Limited</creatorcontrib><title>Pyrazolo[1,5-a]pyrimidine derivatives</title><description>The Pyrazolo[1,5-a]pyrimidine derivatives represented by formula I and their pharmaceutically acceptable salts exhibit excellent MAPKAP-K2 inhibiting activity. Drugs comprising the compounds as effective ingredients are therefore expected to be useful as therapeutic or prophylactic agents for MAPKAP-K2 mediated disorder, such as inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth.</description><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2010</creationdate><recordtype>patent</recordtype><sourceid>EFH</sourceid><recordid>eNrjZFANqCxKrMrPyY821DHVTYwtqCzKzM1MycxLVUhJLcosSyzJLEst5mFgTUvMKU7lhdLcDApuriHOHrqlxQWJJal5JcXx6UWJIMrA3MzM3MDYzJgIJQAmBSg4</recordid><startdate>20100223</startdate><enddate>20100223</enddate><creator>Kosugi, Tomomi</creator><creator>Imai, Minoru</creator><creator>Makino, Hiroaki</creator><creator>Takakuwa, Mika</creator><creator>Unoki, Gen</creator><creator>Kataoka, Kenichiro</creator><creator>Mitchell, Dale Robert</creator><creator>Simpson, Donald James</creator><creator>Harris, Clifford John</creator><creator>Le, Joelle</creator><creator>Yamakoshi, Yuko</creator><scope>EFH</scope></search><sort><creationdate>20100223</creationdate><title>Pyrazolo[1,5-a]pyrimidine derivatives</title><author>Kosugi, Tomomi ; Imai, Minoru ; Makino, Hiroaki ; Takakuwa, Mika ; Unoki, Gen ; Kataoka, Kenichiro ; Mitchell, Dale Robert ; Simpson, Donald James ; Harris, Clifford John ; Le, Joelle ; Yamakoshi, Yuko</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-uspatents_grants_076670363</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2010</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Kosugi, Tomomi</creatorcontrib><creatorcontrib>Imai, Minoru</creatorcontrib><creatorcontrib>Makino, Hiroaki</creatorcontrib><creatorcontrib>Takakuwa, Mika</creatorcontrib><creatorcontrib>Unoki, Gen</creatorcontrib><creatorcontrib>Kataoka, Kenichiro</creatorcontrib><creatorcontrib>Mitchell, Dale Robert</creatorcontrib><creatorcontrib>Simpson, Donald James</creatorcontrib><creatorcontrib>Harris, Clifford John</creatorcontrib><creatorcontrib>Le, Joelle</creatorcontrib><creatorcontrib>Yamakoshi, Yuko</creatorcontrib><creatorcontrib>Teijin Pharma Limited</creatorcontrib><collection>USPTO Issued Patents</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Kosugi, Tomomi</au><au>Imai, Minoru</au><au>Makino, Hiroaki</au><au>Takakuwa, Mika</au><au>Unoki, Gen</au><au>Kataoka, Kenichiro</au><au>Mitchell, Dale Robert</au><au>Simpson, Donald James</au><au>Harris, Clifford John</au><au>Le, Joelle</au><au>Yamakoshi, Yuko</au><aucorp>Teijin Pharma Limited</aucorp><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Pyrazolo[1,5-a]pyrimidine derivatives</title><date>2010-02-23</date><risdate>2010</risdate><abstract>The Pyrazolo[1,5-a]pyrimidine derivatives represented by formula I and their pharmaceutically acceptable salts exhibit excellent MAPKAP-K2 inhibiting activity. Drugs comprising the compounds as effective ingredients are therefore expected to be useful as therapeutic or prophylactic agents for MAPKAP-K2 mediated disorder, such as inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_uspatents_grants_07667036 |
| source | USPTO Issued Patents |
| title | Pyrazolo[1,5-a]pyrimidine derivatives |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T16%3A15%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-uspatents_EFH&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Kosugi,%20Tomomi&rft.aucorp=Teijin%20Pharma%20Limited&rft.date=2010-02-23&rft_id=info:doi/&rft_dat=%3Cuspatents_EFH%3E07667036%3C/uspatents_EFH%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |